 To assess whether two doses of dabigatran etexilate 110 mg twice daily b.i.d and 150 mg twice daily b.i.d as compared to unfractionated heparin UFH, both in addition to a standard dual antiplatelet regimen, provide sufficient anticoagulation in the setting of elective percutaneous coronary intervention PCI. 